Bj?rn Nashan, MD, PhD,FACS,FRCSC, FEBS

生命科学学院教授
中国科学技术大学
中国安徽省合肥市黄山路443 号 邮编：230027
电子邮箱:nashan@ustc.edu.cn

教育及任命经历:
11/2017 – 现在: 中国科学技术大学附属第一医院外科学教授
07/2007 - 09/2017: 德国汉堡大学肝胆外科及移植中心主任，外科学教授
11/2003 - 07/2007: 加拿大达尔豪斯大学伊丽莎白女王二世健康科学中心器官移植科主任，免疫、微生物学及外科学教授
04/1994 – 10/2003: 德国汉诺威大学附属医院器官移植及内脏外科高级医师
04/1988 – 03/1994: 德国汉诺威大学附属医院心脏、胸、血管外科，急诊科，腹部外科及器官移植中心住院医师
02/1986 – 03/1988: 汉诺威大学附属医院腹部外科住院医师及器官移植中心移植免疫实验室研究员

研究兴趣及方向:
移植免疫学，肿瘤生物学的分子信号研究，临床研究


主要研究方向：
临床研究: 肝脏原发性和继发性恶性肿瘤，肝脏切除术的外科学技术(如：联合肝脏分割和门静脉结扎的分阶段肝切除术), 劈离式肝移植和小儿肝移植，活体肝获取术及肝移植，CT 三维重建，腹腔镜下和后腹膜腹腔镜下活体肾脏获取术
免疫抑制相关研究（CNI Minimisation 个体化研究，免疫抑制的个体化研究，免疫抑制剂的1-3 期临床研究）


基础研究: 分子肿瘤学（AKT，mTOR 信号通路）移植免疫学（IL-2R，CNI，mTOR 和 signal 2 信号通路，肝肾慢性排斥反应的机制研究）

摘选部分发表论文(302 篇中摘选 25 篇):
1. Nashan B, Schlitt H J, Tusch G, Oldhafer K, Ringe B, Wagner S, Pichlmayr R. Biliarymalignancies in primary sclerosing cholangitis. Timing for liver transplantation. Hepatology1996. 23:1105-11
2. Nashan B, Schlitt H J, Schwinzer R, Ringe B, Kuse E, Tusch G, Wonigeit K, Pichlmayr R.Immunoprophylaxis with a monoclonal anti IL-2 receptor antibody in liver transplantedpatients. Transplantation1996; 61:546-54
3. Nashan B, Moore R, Amlot P, A G Schmidt, K Abeywickrama, J P Soulillou. Randomisedtrial of basiliximab versus placebo for control of acute cellular rejection in renal allograftrecipients. The Lancet 1997; 350:1193-8.
4. Nashan B, Light S, Hardie IR, Lin A, Johnson R. Reduction of acute renal allograft rejection by daclizumab. Transplantation 1999; 67:110-5.
5. Neipp M, G Offner G, R Lück R, Ehrich JHH, Strehlau J, Schlitt H J, Klempnauer J, Nashan B. Kidney transplantation in small children: Donor selection and technical consideration. Transplantation. 2002; 73: 409-16.
6. Nashan B, Curtis J, Ponticelli C, Mourad G, Jaffe J, Haas T on behalf of the 156 StudyGroup. Everolimus in Combination with Reduced-Exposure Cyclosporine in de novo RenalTransplant. Recipients: Results of a 3-Year Phase II, Randomized, Multicenter, Open- Label Study. Transplantation2004; Nov 15;78(9):1332-40.
7. Neipp M, Jackobs S, Becjer T, Lueck R, Meyer zu Vilsendorf A, Winny M, Klempnauer J, Nashan B. Living Donor Nephrectomy: Flank Incision vs. Anterior Vertical Mini-Incision.Transplantation 2004; 15;78(9):1356-61.
8. Vincenti F, Larsen C, Durrbach A, Wekerle T, Nashan B, Blancho G, Lan P, Grinyo J, Halloran P F, Solez K, Hagerty D, Levy E, Zhou W, Natarajan K, Charpentier B; BelataceptStudy Group. Costimulation blockade with belatacept in renal transplantation. N Engl J Med. 2005; 353:770-81.
9. Frericks BB, Kirchhoff TD, Shin H O, Stamm G, Merkesdal S, Abe T, Schenk A, Peitgen HO, Klempnauer J, Galanski M, Nashan B. Preoperative volume calculation of the hepaticvenous draining areas with multi-detector row CT in adult living donor liver transplantation: impact on surgical procedure. Eur Radiol. 2004 Feb;14(2):326-33.
10. Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, Margreiter R, Hugo C, Grinyó JM, Frei U, Vanrenterghem Y, Daloze P, Halloran; ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007 Dec 20;357(25):2562-75.
11. Nashan B, Saliba F, Durand F, Barcéna R, Herrero J I, Mentha G, Neuhaus P, Bowles M, Patch D, Bernardos A, Klempnauer J, Bouw R, Ives, R J Mamelok, D Mc Kay, M Truman, P Marotta. Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients.Liver Transpl. 2009 Feb;15(2):136-47.
12. Vincenti F, Blancho G, Durrbach A, Friend P, Grinyo J, Halloran P F, Klempnauer J, Lang P, Larsen C P, Mühlbacher F, Nashan B, Soulillou J P, Vanrenterghem Y, Wekerle T, Agarwal M, Gujrathi v, Shen J, R Shi R, Townsend R, Charpentier B. Five-year safety and efficacy of belatacept in renal transplantation.J Am Soc Nephrol. 2010. Sep;21(9):1587-96. PMID:**
13. Friman S, Arns W, Nashan B, Vincenti F, Banas B, Budde K, Cibrik D, Chan L, Klempnauer J, Mulgaonkar S, Nicholson M, Wahlberg J, Wissing KM, Abrams K, Witte S, Woodle ES. Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients. Am J Transplant. 2011 Jul;11(7):1444-55.
14. Grabinski N, Ewald F, Hofmann BT, Staufer K, Schumacher U, Nashan B, Jücker M. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.Mol Cancer. 2012 Nov 20;11:85.
15. Ewald F, Grabinski N, Grottke A, Windhorst S, N?rz D, Carstensen L, Staufer K, Hofmann BT, Diehl F, David K, Schumacher U, Nashan B, Jücker M. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma. Int J Cancer. 2013 Apr 16.
16. David KA, Unger FT, Uhlig P, Juhl H, Moore HM, Compton C, Nashan B, D?rner A, de Weerth A, Zornig C. Surgical procedures and postsurgical tissue processing significantly affect expression of genes and EGFR-pathway proteins in colorectal cancer tissue. Oncotarget. 2014 Nov 30;5(22):11017-28. doi: 10.18632/oncotarget.2669.
17. Ewald F, N?rz D, Grottke A, Hofmann BT, Nashan B, Jücker, M. Dual Inhibition of PI3K- AKT-mTOR- and RAF-MEK-ERK-signalling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors. Invest New Drugs. 2014 Dec;32(6):1144- 54. doi: 10.1007/s10637-014-0149-7.
18. N?rz D, Grottke A, Bach J, Herzberger C, Hofmann BT, Nashan B, Jücker M, Ewald F. Discontinuing MEK inhibitors in tumor cells with an acquired resistance increases migration and invasion.Cell Signal. 2015 Jul 22. pii: S0898-6568(15)00213-2. doi:10.1016/j.cellsig.2015.07.016.
19. Stein A, Arnold D, Bridgewater J, Goldstein D, Jensen LH, Klümpen HJ, Lohse AW, Nashan B, Primrose J, Schrum S, Shannon J, Vettorazzi E, Wege H. Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - arandomized, multidisciplinary, multinational phase III trial. BMC Cancer. 2015 Jul
31;15:564. doi: 10.1186/s12885-015-1498-0.
20. Li J, Kantas A, Ittrich H, Koops A, Achilles E G, Fischer L, Nashan B. Avoid All-Touch by Hybrid ALPPS to Achieve Oncological Efficacy. Ann Surg. 2016 Jan;263(1):e6-7. doi:10.1097/SLA.0845. PMID:**
21. Nashan B, Hugo C, Strassburg CP, Arbogast H, Rahmel A, Lilie H. Transplantation in Germany. Transplantation. 2017 Feb;101(2):213-218. doi:10.1097/TP.1554
22. Schütz E, Fischer A, Beck J, Harden M, Koch M, Wuensch T, Stockmann M,Nashan B, Kollmar O, Matthaei J, Kanzow P, Walson PD, Brockm?ller J, Oellerich M. Graft-derived cell-free DNA, a non-invasive early rejection and graft damage marker in liver transplantation: A prospective, observational, multicentre cohort study. PLoS Med. 2017 Apr 25;14(4):e**. doi: 10.1371/journal.pmed.**. eCollection 2017 Apr
23. Lunemann S, Martrus G, Goebels H, Kautz T, Langeneckert A, Salzberger W, Koch M, J Bunders M, Nashan B,van Gisbergen KPJM, Altfeld M. Hobit expression by a subset of human liver-resident CD56bright Natural Killer Cells. Sci Rep. 2017 Jul 27;7(1):6676. doi:10.1038/s41598-017-06011-7.
24. Herden U, Fischer L, Koch M, Li J, Achilles E, Nashan B. Outcome following right- extended split liver transplantation in the recent transplant era: Single-centre analysis of a German transplant centre. Clin Transplant. 2018 Jul;32(7):e13288. doi:10.1111/ctr.13288.
25. Li J, Koch M, Kramer K, Kloth K, Abu Ganim AR, Scheidat S, Rinninger F, Thaiss F, Gulati A, Herden U, Achilles E, Fischer L, Nashan B. Dual antibody induction and de novo use of everolimus enable low-dose tacrolimus with early corticosteroid withdrawal in simultaneous pancreas-kidney transplantation. Transpl Immunol. 2018 Jun 6. pii: S0966- 3274(17)30115-6. doi: 10.1016/j.trim.2018.06.001.
招生招聘：
实验室招聘免疫学、分子生物学等相关背景的博士后和特任（副）研究员，待遇从优。同时热忱欢迎对本实验室研究方向感兴趣的本科生前来攻读博士学位。简历请发送至:bjoern.nashan@gmail.com